Climate-Tech Startups in India: C-CAMP Backs 11 Biotech Ventures

What happened

The Centre for Cellular and Molecular Platforms (C-CAMP) has selected 11 early-stage companies for a climate and sustainability programme run with the Ashraya Hastha Trust (AHT).12 Each selected startup can receive up to ₹50 lakh in funding. They also get access to high-end incubation laboratories, scientific and business mentoring, help scaling products for market deployment, and introductions to industry stakeholders.1

The cohort includes:

• Genepath Diagnostics India
• Prodancy
• AeroDel Technology Innovations
• Intello Labs
• String Bio
• Tealaa Innovations
• Ossus Biorenewables
• BPC Bio Bioproducts (Amylo)
• Earthkind Foods Biotech
• Intrinsic Foundries (IIOT Innovation)
• Bisket Labs1

The programme describes their work as falling into three areas. The first is cutting greenhouse gas emissions and carbon footprints. The second is enabling healthcare that can withstand climate change. The third is advancing climate-resilient, sustainable agriculture.1

Why the cohort's shape matters

The most telling detail is the mix of companies. This is not a cohort built mainly around solar panels, batteries or electric vehicles, the hardware most often linked with "climate tech." The list leans toward biology: diagnostics, bioproducts, biorenewables and food biotechnology, alongside agriculture-focused ventures.1 That reflects C-CAMP's roots as a life-sciences platform. It also reflects a growing view that biotechnology can play a meaningful role in decarbonisation and adaptation.

Including "climate-resilient healthcare" as its own category stands out.1 Most climate funding still targets mitigation, meaning reducing emissions. Adaptation gets less attention, even though shifting disease patterns, heat stress and changes in agriculture are likely to affect countries like India sooner and harder. Putting diagnostics companies in a climate cohort shows that adaptation is being treated as a real investment area.

Agriculture plays a similar double role. Farming is both a source of emissions and one of the sectors most exposed to a changing climate. Startups working on sustainable or resilient agriculture therefore address both sides of the problem, which may explain why the theme is so prominent in the selection.1

Reading the size of the cheque

It helps to be realistic about scale. Up to ₹50 lakh per company is a modest sum, roughly in the tens of thousands of US dollars.1 That covers early validation work, not commercial manufacturing. For deep-tech and biotech ventures, the hardest stretch is usually the move from lab proof to pilot plant or field trial. Capital needs rise sharply at that stage, while revenue is still far off.

This is why the non-cash support may matter as much as the money. Access to well-equipped incubation labs removes one of the biggest early costs for biology-based startups, because buying instruments or renting specialised wet-lab space can quickly drain a small grant. Mentorship on both science and business, help with scale-up, and introductions to industry players address the other common failure point: turning a promising technology into something a customer will buy.1

The best way to read the programme, then, is as an on-ramp rather than a full financing solution. Grant-and-incubation schemes like this one take on technical risk early, so these companies are more fundable when they approach venture investors or corporate partners later.

The philanthropic angle

The partnership with the Ashraya Hastha Trust is also worth noting.12 Pairing an incubation platform with a philanthropic trust is a familiar way to fund work that is too early or too uncertain for conventional investors. Patient, non-dilutive money can let founders run experiments that commercial backers would not pay for. In climate biotech, timelines are long and technical uncertainty is high, so that kind of capital fills a real gap.

What to watch

The announcement itself is limited. It names the companies and the support on offer but gives few details about the individual technologies or the milestones each startup must reach.1 Outside observers will want to know how many of these ventures go on to raise follow-on funding, sign industry partnerships or reach field deployment over the next few years. Those outcomes will show whether this model actually speeds climate biotech to market.

For now, the selection offers a useful snapshot. It suggests that India's climate innovation pipeline is increasingly coming from labs focused on biology, food and health, not only from energy hardware. If the support works as intended, some of these 11 companies could become proof that biotech belongs at the centre of the country's climate strategy.